NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis $1.46 -0.10 (-6.41%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.38▼$1.5850-Day Range$1.46▼$1.9052-Week Range$1.08▼$3.79Volume556,313 shsAverage Volume1.50 million shsMarket Capitalization$95.58 millionP/E RatioN/ADividend YieldN/APrice Target$10.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Regulus Therapeutics alerts: Email Address Regulus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside639.7% Upside$10.80 Price TargetShort InterestHealthy6.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$7,280 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.80) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.26 out of 5 starsMedical Sector600th out of 910 stocksPharmaceutical Preparations Industry277th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingRegulus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRegulus Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Regulus Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.77% of the float of Regulus Therapeutics has been sold short.Short Interest Ratio / Days to CoverRegulus Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Regulus Therapeutics has recently decreased by 8.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegulus Therapeutics does not currently pay a dividend.Dividend GrowthRegulus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RGLS. Previous Next 2.0 News and Social Media Coverage News SentimentRegulus Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Regulus Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for RGLS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regulus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,280.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.35% of the stock of Regulus Therapeutics is held by insiders.Percentage Held by Institutions92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regulus Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.80) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regulus Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regulus Therapeutics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegulus Therapeutics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regulus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Regulus Therapeutics Stock (NASDAQ:RGLS)Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More RGLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGLS Stock News HeadlinesAugust 28, 2024 | prnewswire.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesAugust 14, 2024 | finance.yahoo.comCompanies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In GrowthSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal TrialAugust 9, 2024 | investorplace.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024August 8, 2024 | prnewswire.comRegulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent UpdatesAugust 6, 2024 | prnewswire.comRegulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth ConferenceAugust 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics on RGLS8429’s Potential in ADPKD MarketSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…July 9, 2024 | prnewswire.comRegulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesJune 24, 2024 | prnewswire.comRegulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)June 4, 2024 | prnewswire.comRegulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesMay 16, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 16, 2024 | prnewswire.comRegulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 13, 2024 | theguardian.comStarwatch: the moon celebrates with a cruise past RegulusMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429May 10, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 9, 2024 | msn.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024See More Headlines Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CUSIP75915K10 CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$10.80 High Stock Price Target$28.00 Low Stock Price Target$3.00 Potential Upside/Downside+639.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.47% Return on Assets-49.37% Debt Debt-to-Equity RatioN/A Current Ratio19.07 Quick Ratio19.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book1.39Miscellaneous Outstanding Shares65,466,000Free Float62,618,000Market Cap$95.58 million OptionableOptionable Beta1.63 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Joseph P. Hagan M.B.A. (Age 55)CEO & Director Comp: $958.23kMs. Crispina Calsada CPA (Age 54)Chief Financial Officer Comp: $579.3kMr. Christopher Ray Aker J.D. (Age 63)Senior VP, General Counsel & Corporate Secretary Comp: $575.94kDr. Preston S. Klassen M.D. (Age 55)M.H.S., President, Head of Research & Development and Director Mr. Daniel J. Penksa (Age 38)VP of Finance & Controller Dr. Claire Susan Padgett M.S.M.T., Ph.D., Senior Vice President of Clinical OperationsDr. Rekha Garg M.D.M.S., Senior Vice President of Clinical Development & RegulatoryMr. Edmund Lee Ph.D.Vice President of Translational MedicineMore ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMLexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsCVI Holdings LLCSold 1,005,238 shares on 8/15/2024Ownership: 0.613%Renaissance Technologies LLCBought 42,600 shares on 8/9/2024Ownership: 0.180%Victory Capital Management Inc.Sold 6,760 shares on 8/5/2024Ownership: 0.552%Rhumbline AdvisersBought 76,472 shares on 8/1/2024Ownership: 0.117%Bank of New York Mellon CorpBought 197,193 shares on 7/26/2024Ownership: 0.301%View All Insider TransactionsView All Institutional Transactions RGLS Stock Analysis - Frequently Asked Questions How have RGLS shares performed this year? Regulus Therapeutics' stock was trading at $1.28 at the start of the year. Since then, RGLS stock has increased by 14.1% and is now trading at $1.46. View the best growth stocks for 2024 here. How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). When did Regulus Therapeutics' stock split? Shares of Regulus Therapeutics reverse split before market open on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO? 2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Regulus Therapeutics' major shareholders? Top institutional investors of Regulus Therapeutics include CVI Holdings LLC (0.61%), Victory Capital Management Inc. (0.55%), Bank of New York Mellon Corp (0.30%) and Renaissance Technologies LLC (0.18%). Insiders that own company stock include Joseph P Hagan, Kathryn J Collier, Crispina Calsada and Denis Drygin. View institutional ownership trends. How do I buy shares of Regulus Therapeutics? Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE) and Exelixis (EXEL). This page (NASDAQ:RGLS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
